Provision Cost

A provision of the US 21st Century Cures Act that gives an additional six months of exclusive marketing rights to companies whose drugs are approved to treat rare diseases will cost the federal government some $869 million between 2016 and 2025, reports Ed Silverman at Pharmalot.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.